Tag: MTBC

Blue Horseshoe Stocks: PIXY Review & More

ShiftPixy, Inc. PIXY

As we were mentioning on Monday morning, we included PIXY in Friday’s report on its first ever trading day. Generally speaking we don’t tend to cast our lot in with brand new IPO’s, but a trusted source in our network gave us a heads-up on PIXY, and didn’t let us down.

We of course passed it along to our readers immediately in our premarket report on Friday, and the stock, after two trading days has made some really nice progress.

From the initial opening price of 6.30 we observed in PIXY, it went on to hit a high of 9.70 to kick off the short trading week on Monday. That marks a two-day swing of 54% for this newly-trading juggernaut. We’ll continue to be on the lookout for PIXY to keep recording higher base levels of support.

Opexa Therapeutics, Inc. OPXA

An honorable mention from Monday’s report is OPXA, especially considering that sessions just prior to a holiday break are typically low-key affairs.

The stock put up a solid intraday performance, running 35% from a low of a dollar up to 1.35, and pulling back into the close at 1.15. However, premarket activity this morning has seen the stock trade back to just below Monday’s high. This is one we’ll want to keep on our radar for the time being.

Aphria, Inc. APHQF

We’ve been familiar with APHQF for quite a time, but today will be the first occasion we’ve actually mentioned it in our reports.

Today, we wanted to point out that the company released two PR’s yesterday, the more significant of which was the announcement of a 1-year cannabis supply deal with a licensed Canadian medical provider which will bring upwards of $5M in revenue beginning midway through next year. We’ll provide links to both PR’s so you can check them out for yourself.

Aphria Inks Major Wholesale Supply Agreement With Scientus Pharma, Health Canada Licensed Dealer – 07/04

Tokyo Smoke to open Canadian flagship retail store on Queen Street West – 07/04

Extended Watchlist:
OTTV, CLSN, MSDI, MTBC, TOPS, GBR, FCEL

Blue Horseshoe Stocks: LODE, Options & More

Potential Bottom-Plays

Comstock Mining, Inc. LODE – We’re coming across a serious bottom-bounce candidate in LODE this morning. The stock has been in a general downtrend all year long, and was recently beaten back so severely that a rebound was inevitable. That began yesterday, and now we’re very interested to track the activity and see if we can confirm a sustained reversal on this one.

Taking a look at the included snapshot of the LODE chart, it would quite frankly be a little surprising if this play didn’t see a continued rebound, and it’s currently trading up in the premarket, so we’ll surely want to keep an eye peeled as the session kicks off.

Another notable aspect of this play is that the company must find a way to re-attain a share price of at least a dollar by November, or face delisting from the AMEX.

______

MabVax Therapeutics Holdings, Inc. MBVX –  Another similar looking chart striking us as a potential bottom-bounce play. MBVX has been trending down since last fall, and it appears as if it’s ready to make a move off of its recently established annual lows, helped along by a key PR.

The company reported positive phase I results for its MVT-2163 ImmunoPET Imaging Agent, an antibody discovery platform focused on the treatment of cancer. (>>View PR) It’s causing a considerable gap-up here in the premarket, and we’ll be quite interested to follow along with the activity.

The Kroger Co. KR  – Options Idea

KR set its own 52-week lows this spring, and has recently been making a comeback on the chart. They’ve also got earnings coming tomorrow, so we thought we’d formulate an options idea running into that release.

We’ll be looking at the KR Weekly $29 and $30 Calls, which could see some nice action, especially if the company’s earnings beat expectations tomorrow.

Extended Watchlist:
ABIL, MTBC, MBOT, SBGL, LINU, EKSO

Blue Horseshoe Stocks: Stellar Options Calls & More

Valeant Pharmaceuticals, Inc. VRX – Options Recap

In yesterday morning’s premarket report, we noted that VRX had been coming off of recent annual lows, had a beat on earnings, and was up considerably in early trading.

Our exact words were “We want to formulate an options idea to coincide with the increased activity and expected price action in a stock in this position. We’ve seen this sort of pattern many times before, and if things play out similarly here, the VRX Weekly $10.50-12 Calls could be in line to see considerable gains.” Things did play out similarly. We did indeed see considerable gains, and quite frankly, that’s an understatement.

As VRX itself traded from 10.57 to 12.43, our targeted options calls posted astronomical moves on the day, giving traders a chance to grab a piece of the following gains:

$10.50 Calls – Range: .40-.1.92 – Max Gain: 380%
$11 Calls – Range: .18-1.50 – Max Gain: 733%
$11.50 Calls – Range: .08-1.05 – Max Gain: 1212%
$12 Calls – Range: .02-.74 – Max Gain: 3600%

This wasn’t even the first percentage gain in the thousands that we’ve rooted out in the past week. The SPY Weekly $238-50-239.50 Calls that we highlighted in Friday morning’s premarket report yielded a 4600% gainer on that day. Both of these plays serve as perfect examples of why we don’t limit our daily reports to stocks alone.

Cleantech Solutions International, Inc. CLNT

We did have a very nice play on the stock side of things as well yesterday, after we tagged CLNT in our extended watchlist. It ended up making a solid early push from a low of 4.11, and ran as high as 6.99 inside the first hour of trading.

That was good for intraday gains of up to 70% which we feel is quite good for a stock in this price range. CLNT is pulling back in premarket, but we will remain interested in possible bounce activity in the event that it holds support above yesterday’s swing low.


Proteon Therapeutics, Inc. PRTO

There’s an interesting situation unfolding with PRTO that warrants placing the stock on watch today. Despite reporting Q1 losses of $6.5M, the stock is gapping up heavily on the strength of a concurrent announcement. It pertains to the fact that the company’s investigatory treatment, vonapanitase, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Whenever such FDA news hits wires the resultant activity on the chart is sure to be interesting, which is evidenced by the the fact that traders are ignoring the disappointing quarterly figures that coincided with this event. Thus we are eager to track PRTO as we head through midweek.

Extended Watchlist:
ASTI, BZUN, LBIO, AAXN, ARGS, MTBC, REXX